| CRISPR-Cas9-based mutagenesis frequently provokes on-target mRNA misregulation R Tuladhar, Y Yeu, J Tyler Piazza, Z Tan, J Rene Clemenceau, X Wu, ... Nature communications 10 (1), 4056, 2019 | 197 | 2019 |
| Phosphodiesterase 10A: a novel target for selective inhibition of colon tumor cell growth and β-catenin-dependent TCF transcriptional activity N Li, K Lee, Y Xi, B Zhu, BD Gary, V Ramírez-Alcántara, E Gurpinar, ... Oncogene 34 (12), 1499-1509, 2015 | 74 | 2015 |
| Extra-mitochondrial prosurvival BCL-2 proteins regulate gene transcription by inhibiting the SUFU tumour suppressor X Wu, L Zhang, J Toombs, YC Kuo, JT Piazza, R Tuladhar, Q Barrett, ... Nature cell biology 19 (10), 1226-1236, 2017 | 50 | 2017 |
| The yin and yang of ERBB4: tumor suppressor and oncoprotein LM Lucas, V Dwivedi, JI Senfeld, RL Cullum, CP Mill, JT Piazza, IN Bryant, ... Pharmacological Reviews 74 (1), 18-47, 2022 | 39 | 2022 |
| Phosphodiesterase 10A is overexpressed in lung tumor cells and inhibitors selectively suppress growth by blocking β-catenin and MAPK signaling B Zhu, A Lindsey, N Li, K Lee, V Ramirez-Alcantara, JC Canzoneri, ... Oncotarget 8 (41), 69264, 2017 | 31 | 2017 |
| CRISPR R Tuladhar, Y Yeu, JT Piazza, Z Tan, JR Clemenceau, X Wu, TH Hwang Cas9-based mutagenesis frequently provokes on-target mRNA misregulation …, 2019 | 6 | 2019 |
| CRISPR-Cas9-based mutagenesis frequently provokes on-target mRNA misregulation. Nat. Commun. 10: 4056 R Tuladhar, Y Yeu, JT Piazza, Z Tan, JR Clemenceau, XF Wu, Q Barrett, ... | 5 | 2019 |
| Development and application of high-throughput screens for the discovery of compounds that disrupt ErbB4 signaling: Candidate cancer therapeutics RL Cullum, LM Lucas, JI Senfeld, JT Piazza, LT Neel, K Whig, L Zhai, ... Plos one 15 (12), e0243901, 2020 | 4 | 2020 |
| Phosphodiesterase 10, a novel target in colon cancer. S Russo, N Li, K Lee, Y Xi, B Zhu, B Gary, V Ramirez, E Gurpinar, ... Journal of Clinical Oncology 32 (3_suppl), 503-503, 2014 | 3 | 2014 |
| Abstract A19: Discovery and characterization of selective and nonselective inhibitors of ErbB4 signaling: Putative targeted melanoma therapeutics LM Lucas, RL Cullum, JI Senfeld, LJ Cook, MH Harris, DZ Kaufmann, ... Cancer Research 80 (19_Supplement), A19-A19, 2020 | | 2020 |
| Discovery and characterization of selective and nonselective inhibitors of ErbB4 signaling: Putative targeted melanoma therapeutics. LM Lucas, RL Cullum, JI Senfeld, LJ Cook, MH Harris, DZ Kaufmann, ... CANCER RESEARCH 80 (19), 40-41, 2020 | | 2020 |
| Charitable gifting system and method of use JT Piazza US Patent App. 16/179,931, 2019 | | 2019 |
| Gene deletion and rescue by crispr-mediated elimination of exon splicing enhancers L Lum, R Tuladhar, TH Hwang, YEU Yunku, JT Piazza, Q Barrett US Patent App. 16/003,683, 2018 | | 2018 |
| Gene architecture influences on the outcome of INDEL‐based genome editing R Tuladhar, Y Yeu, JT Piazza, J Clemenceau, X Wu, Z Tan, D Mathews, ... The FASEB Journal 32, 649.8-649.8, 2018 | | 2018 |
| Abstract A159: Characterization of putative ErbB4 antagonists: targeted melanoma drug discovery RL Cullum, LM Lucas, JT Piazza, JI Senfeld, LT Neel, RB Gupta, ... Molecular Cancer Therapeutics 17 (1_Supplement), A159-A159, 2018 | | 2018 |
| Screening methodologies for the discovery of small molecule melanoma therapeutics targeted at the ErbB4 receptor tyrosine kinase RL Cullum, JT Piazza, JI Senfeld, LT Neel, RB Gupta, AE David, DJ Riese Cancer Research 77 (13_Supplement), 1245-1245, 2017 | | 2017 |
| Phosphodiesterase 10A: A novel target for selective inhibition of colon tumor cell growth and Wnt/β-catenin signaling N Li, K Lee, Y Xi, B Zhu, BD Gary, V Ramírez-Alcántara, E Gurpinar, ... Cancer Research 74 (19_Supplement), 1773-1773, 2014 | | 2014 |
| Abstract C182: Phosphodiesterase 10: A novel cancer target. N Li, K Lee, Y Xi, B Zhu, BD Gary, V Ramirez-Alcantara, E Gurpinar, ... Molecular Cancer Therapeutics 12 (11_Supplement), C182-C182, 2013 | | 2013 |
